Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.

Abstract

BACKGROUND/AIM:

Matrix-producing breast carcinoma (MPBC) is a rare and usually aggressive triple-negative breast cancer (TNBC). In the present report, we determined the drug sensitivity for a triple-negative MPBC using a patient-derived orthotopic xenograft (PDOX) model.

MATERIALS AND METHODS:

The PDOX model was established in the left 2nd mammary by surgical orthotopic implantation (SOI). MPBC PDOX models were randomized into 4 groups (6 mice per group) when the tumor volume became 80 mm3: G1, control group; G2, cisplatinum group [intraperitoneal (i.p.) injection, weekly, for 2 weeks]; G3, paclitaxel group (i.p., weekly, for 2 weeks); G4, eribulin group [intravenous (i.v.) injection, weekly, for 2 weeks]. All mice were sacrificed on day 15. Tumor volume and body weight were measured one time per week.

RESULTS:

The MPBC PDOX model was resistant to cisplatinum (p=0.800). Paclitaxel suppressed tumor growth compared to the control group (p=0.009). However, only eribulin regressed the tumor (p=0.001).

CONCLUSION:

Eribulin has clinical potential for triple-negative MPBC patients.

• Authors: Jun Yamamoto, Takuya Murata, Norihiko Sugisawa, Takashi Higuchi, Yoshihiko Tashiro, Hiroto Nishino, Sachiko Inubushi, Y U Sun, Hyein Lim, Kentaro Miyake, Koichiro Shimoya, Tsunehisa Nomura, Junichi Kurebayashi, Hirokazu Tanino, Chihiro Hozumi, Michael Bouvet, Shree Ram Singh, Itaru Endo, Robert M Hoffman
• Journal: Anticancer research (Anticancer Res) Vol. 40 Issue 5 Pg. 2475-2479 (May 2020) ISSN: 1791-7530 [Electronic] Greece
• PMID: 32366391 (Publication Type: Journal Article)
• Copyright: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Biomarkers, Tumor
• Furans
• Ketones
• eribulin
• Paclitaxel
• Cisplatin

Topics

• Animals
• Biomarkers, Tumor
• Cisplatin (pharmacology, therapeutic use)
• Disease Models, Animal
• Drug Resistance, Neoplasm (drug effects)
• Female
• Furans (pharmacology, therapeutic use)
• Humans
• Ketones (pharmacology, therapeutic use)
• Mice
• Paclitaxel (pharmacology)
• Treatment Outcome
• Triple Negative Breast Neoplasms (drug therapy, etiology, metabolism, pathology)
• Tumor Burden (drug effects)
• Tumor Cells, Cultured
• Xenograft Model Antitumor Assays